98%
921
2 minutes
20
Background: microRNAs (miRNAs) are small, noncoding RNA molecules that are now thought to regulate the expression of many mRNAs. They have been implicated in the etiology of a variety of complex diseases, including Tourette's syndrome, Fragile x syndrome, and several types of cancer.
Results: We hypothesized that schizophrenia might be associated with altered miRNA profiles. To investigate this possibility we compared the expression of 264 human miRNAs from postmortem prefrontal cortex tissue of individuals with schizophrenia (n = 13) or schizoaffective disorder (n = 2) to tissue of 21 psychiatrically unaffected individuals using a custom miRNA microarray. Allowing a 5% false discovery rate, we found that 16 miRNAs were differentially expressed in prefrontal cortex of patient subjects, with 15 expressed at lower levels (fold change 0.63 to 0.89) and 1 at a higher level (fold change 1.77) than in the psychiatrically unaffected comparison subjects. The expression levels of 12 selected miRNAs were also determined by quantitative RT-PCR in our lab. For the eight miRNAs distinguished by being expressed at lower microarray levels in schizophrenia samples versus comparison samples, seven were also expressed at lower levels with quantitative RT-PCR.
Conclusion: This study is the first to find altered miRNA profiles in postmortem prefrontal cortex from schizophrenia patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852419 | PMC |
http://dx.doi.org/10.1186/gb-2007-8-2-r27 | DOI Listing |
Acta Pharmacol Sin
September 2025
Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong-Hong Kong Joint Laboratory for Psychiatric Disorders, Guangdong Province Key Laboratory of Psychiatric Disorders, Guangdong Bas
Recent investigations into the rapid antidepressant effects of ketamine, along with studies on schizophrenia-related susceptibility genes, have highlighted the GluN2A subunit as a critical regulator of both emotion and cognition. However, the specific impacts of acute pharmacological inhibition of GluN2A-containing NMDA receptors on brain microcircuits and the subsequent behavioral consequences remain poorly understood. In this study, we first examined the effects of MPX-004, a selective GluN2A NMDA receptor inhibitor, on behavior within the dorsomedial prefrontal cortex (dmPFC).
View Article and Find Full Text PDFJ Neurosci
September 2025
Center for Neural Science, New York University, New York, New York 10003.
J Neurosci
September 2025
Psychiatry, University of Minnesota, Minneapolis, Minnesota 55455
Deep brain stimulation (DBS) is an emerging treatment for otherwise treatment-refractory psychiatric disorders. It can produce remarkable clinical results in expert hands, but has not fared as well in controlled, multisite trials. That difficulty with scaling up arises in part because DBS' mechanisms are poorly understood, meaning that it is difficult to objectively identify patients likely to respond and/or to customize stimulation to match individual patients' needs.
View Article and Find Full Text PDFJ Neurosci
September 2025
Department of Psychology, University of California, Los Angeles.
Humans frequently make decisions that impact close others. Prior research has shown that people have stable preferences regarding such decisions and maintain rich, nuanced mental representations of their close social partners. Yet, if and how such mental representations shape social decisions preferences remains to be seen.
View Article and Find Full Text PDFEncephale
September 2025
Centre de référence régional des pathologies anxieuses et de la dépression, pôle de psychiatrie générale et universitaire, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Inserm U1215, Neurocentre Magendie, 33000 Bordeaux, France. Electronic address:
Neuropathic pain results from an injury or a dysfunction of the somatosensory system. Management of this disease is complex due to a restricted therapeutic arsenal and limited efficacy of currently available treatments. Because of its chronic and disabling nature, neuropathic pain is strongly associated with depressive disorders.
View Article and Find Full Text PDF